Publicaciones en colaboración con investigadores/as de University Hospital of Zurich (19)

2021

  1. Biologicals in atopic disease in pregnancy: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 71-89

  2. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 90-113

2020

  1. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  2. Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019

    Allergy: European Journal of Allergy and Clinical Immunology

  3. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  4. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2445-2476

  5. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

    Nature Medicine, Vol. 26, Núm. 12, pp. 1865-1877

  6. State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 4, pp. 746-760

  7. Type 2 immunity in the skin and lungs

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 7, pp. 1582-1605

2019

  1. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 3, pp. 432-448

2018

  1. Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases

    Allergo Journal International, Vol. 27, Núm. 8, pp. 245-255

2017

  1. Altered fatty acid metabolism and reduced stearoyl-coenzyme a desaturase activity in asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 11, pp. 1744-1752

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 70, Núm. 7, pp. 727-754

2014

  1. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 69, Núm. 9, pp. 1162-1170

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544